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Abstract
Background Energy homeostasis is mediated by the hypothalamus, whose inflammation-induced functional derangements
contribute to the onset of anorexia in cancer. By using functional magnetic resonance imaging (fMRI), we determined the
patterns of hypothalamic activation after oral intake in anorexic (A), non-anorexic (NA) cancer patients, and in controls (C).
Methods Lung cancer patients were considered. Hypothalamic activation was recorded in A and NA patients and in C by
fMRI, before (T0), immediately after (T1) the administration of an oral nutritional supplement, and after 15min (T2). The grey
of the hypothalamus and Blood Oxygen Level Dependent (BOLD) intensity were calculated and normalized for basal
conditions. Interleukin (IL)-1, IL-6, tumour necrosis factor (TNF)-α, ghrelin, and leptin plasma levels were measured. A
statistical parametric mapping was used.
Results Thirteen lung cancer patients (7M, 6 F; 9A, 4NA) and 2 C (1M, 1 F) were enrolled. Controls had the lowest BOLD
intensity. At all-time points, anorexic patients showed lower hypothalamic activity compared with NA (P< 0.001) (T0:
585.57 ± 55.69 vs. 667.92 ± 33.18, respectively; T1: 536.50 ± 61.70 vs. 624.49 ± 55.51, respectively; T2: 556.44 ± 58.51 vs.
615.43 ± 71.50, respectively). Anorexic patients showed greater BOLD signal reduction during T0–T1 than NA (8.5% vs.
6.80%, P< 0.001). Independently from the presence of anorexia, BOLD signals modification before and after oral challenge
correlated with basal values of IL-1 and ghrelin (P< 0.001).
Conclusions Hypothalamic activity in A cancer patients is reduced respect to NA and responds differently to oral challenges.
This suggests a central control of appetite dysregulation during cancer anorexia, before, and after oral intake.
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Introduction
Anorexia, i.e. the loss of the desire to eat, is frequently found
among cancer patients, and its presence negatively impacts
on patients’ morbidity, mortality, and quality of life.1,2
Anorexia represents a defensive mechanism against external
insults, in particular infections.3 Nevertheless, during chronic
diseases including cancer, it contributes to the onset of
protein-energy malnutrition and eventually cachexia.4–6
Recent evidences indicate that energy homeostasis, i.e. the
control of energy intake and expenditure, is largely mediated
within the hypothalamus, and centrally produced cytokines
are involved in triggering the molecular changes associated
with the development of cancer-associated anorexia and
cachexia.1,7,8 Also, experimental models of wasting indicate
that muscle proteolysis during disease is influenced by
hypothalamic activity. In particular, centrally produced
pro-inflammatory cytokines appear to facilitate the activity
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of the hypothalamic melanocortin system toward the
promotion of catabolic stimuli.7
During tumour growth, the interaction with the host
immune system triggers a systemic inflammatory response,
whose pathogenesis is primarily mediated by pro-
inflammatory cytokines (i.e. tumour necrosis factor (TNF)-α,
interleukin (IL)-1, IL-6, etc.). At the central level, it has been
postulated that the inflammatory response profoundly alters
the activity of the hypothalamic nuclei, which are involved in
the regulation of energy homeostasis. In particular, pro-
inflammatory cytokines appear to inhibit prophagic neurons
activity, while enhancing the activation of the anorexigenic
neurons.7 Although supported by compelling experimental
evidence, it should be acknowledged that this pathogenic
hypothesis has not been confirmed yet by human studies.9
Indeed, the lack of non-invasive tools to assess human
hypothalamic activity in vivo prevented the possibility to
confirm its role in human cancer anorexia. Indirect evidence,
such as the close association between perturbations of
sympathovagal balance and cancer patients’ outcome,9
appears to confirm the involvement of the hypothalamus in
the metabolic disorders of cancer. Nevertheless, the direct
involvement of the central nervous system during cancer
anorexia in humans remains to be clearly demonstrated.
Indeed, hormonal alterations might play a relevant role in
the dysregulation of food intake during cancer. In fact, several
experimental and clinical data highlighted the possible role of
at least two specific hormones, such as ghrelin (with
prophagic effects)10 and leptin (with anorexigenic effects).11
In the past few years, a sophisticated neuroimaging
technique to study in vivo neurophysiology has become
available, i.e. functional magnetic resonance imaging (fMRI).
By means of this technique, whose features but also
limitations have been largely described,12,13 it is possible to
measure, in a non-invasive and predictable way, the spatial
and temporal patterns of brain activation/inhibition after
specific stimuli. So far, this imaging modality has been used
to explore the relationships between eating behaviour and
neural activity. As an example, fMRI has been used to
correlate gustative stimuli and cerebral activity,12 but no
report exists in the literature regarding its use in cancer
patients before and after food intake. Considering the
influence of changes in appetite on patients’ outcome,2 fMRI
should be implemented in patients to obtain clinically
relevant information and possibly devise therapeutic
strategies.
The primary aim of the present study was to determine the
baseline hypothalamic signals in anorexic and non-anorexic
cancer patients, and to measure the intensity of the
hypothalamic response to a standard meal in the same
population. We also aimed at revealing potential differences
among patterns and at correlating them with the levels of
concurrently measured circulating pro-inflammatory
cytokines.
Secondary aims were to relate the possible altered
circulating levels of ghrelin, leptin, and proinflammatory
cytokines to the presence of anorexia, and to the pattern of
activation/inhibition of specific hypothalamic areas analysed
via the fMRI.
Materials and methods
After approval of the study protocol by the Ethical Committee
at our Institution (Azienda Policlinico Umberto I, Sapienza
University of Rome, Italy), the study was registered on
Clinicaltrials.gov (NCT01564693). Anorexic lung cancer
patients, non-anorexic lung cancer patients, and healthy
individuals (control group) were studied. The sample size
was determined based on previous studies of neuroimaging
available in the literature12,13 and on our preliminary
observations (not published) documenting, during fMRI
scansion, a hypothalamic signals variation of 9% in anorexic
lung cancer patients and 7% in non-anorexic lung cancer
patients (standardized difference of 2% with a standard
deviation of 1%). Therefore, a total of 13 lung cancer patients
guaranteed a power of 90%, at a significance level of 5%, to
detect the difference in hypothalamic activity between
anorexic and non-anorexic patients.
Patients’ selection
Patients with confirmed diagnosis of non-small cell lung
cancer (NSCLC) were considered for the enrollment before
the initiation of any anti-cancer treatment, including surgery
and/or chemo/radiotherapy (treatments naïve), in order to
investigate the effect of cancer-related anorexia.
The inclusion criteria were: age ≥18 years, stage of the
disease IIIB or IV NSCLC, and ability to provide informed
consent.
Exclusion criteria were: patients with concomitant wasting
disease, such as end-stage renal disease, liver cirrhosis or
psychiatric disorders or cognitive impairment, and dysphagia
or mechanical obstruction of the gastrointestinal tract. We
also excluded patients with head motion (i.e. tremor
disorders) and claustrophobia. All study procedures were
performed in accordance with the ethical standards of the
responsible institutional committee on human
experimentation.
Anorexia tools
Approximately 30min before recording hypothalamic activity,
the presence/absence of anorexia was investigated using the
Functional Assessment of Anorexia/Cachexia Therapy
(FAACT) questionnaire, which has been recently endorsed
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by the European Society for Clinical Nutrition and
Metabolism (ESPEN) as a reliable tool to assess disease-
associated anorexia.14 As recently shown, a FAACT score ≤ 30
is indicative of the presence of anorexia.15,16
We also used a specific anorexia questionnaire17
investigating the presence of major symptoms, like meat
aversion, taste and smell alterations, nausea and/or
vomiting, and early satiety. All these symptoms interfere
with eating and are likely related to deranged central
nervous system regulation of feeding behaviour. The patients
reporting one or more of these symptoms were considered
as anorexic.17
A visual analog scale (VAS) consisting of a line of 100mm
was also utilized.18 The extremities of this line are anchored
to ‘no hunger’ (0mm) and ‘hunger’ (100mm). Patients were
asked to place a line on the VAS that corresponded to their
current appetite.18
The time frame of reference for the three appetite tools
was represented by the moment they were completed
(current appetite). We additionally administered the self-
assessment of appetite changes, which investigates present
appetite vs. appetite over the last month (increased,
decreased, or unchanged).16
The percentage of food eaten by each patient at the most
recent meal (ranging from 0% to 100%) was also recorded.
Functional magnetic resonance imaging and oral
nutritional supplementation
On the same day of anorexia assessment, hypothalamic
activation patterns were evaluated in patients and in control
subjects by fMRI. Appetite intensity has been shown to
fluctuate during the day.19 To minimize the influence of
appetite diurnal variation, patients and controls were studied
at the same time of the morning, after an overnight fast
(at least 10 h). Participants kept their eyes closed during fMRI
scansion, with head movement and motion-related artifacts
minimized by using foam pads, as previously described.20
After basal evaluation, all the groups received a standard oral
meal, i.e. a 200mL hypercaloric oral nutritional supplement
(ONS) providing 300 Kcal (Ensure Plus, Abbott, Lake Forest,
IL, USA). Immediately after the ONS intake, which took
approximately 15min, a second fMRI scan was performed
for 15 consecutive minutes. During the entire fMRI scansion
the Blood Oxygen Level Dependent (BOLD) intensity signals
were recorded. Images were obtained using a 3.0 T MRI
system (Verio, Siemens, Erlangen, Germany) equipped with
magnetic field gradients of 45mTm1. Patients were scanned
in supine position with their head placed in an eight-channel
head coil (Head matrix coil, Siemens, Erlangen, Germany).
After a localizer sequence, a high resolution T1 spin echo
image (TR/TE 400/8.4ms, FOV 220mm2, matrix 512 × 512,
slice thickness 4mm, no GAP, 15 slices, 2′50″) was acquired
in sagittal plane. This sequence was performed to identify
the best midsagittal slice where the hypothalamus was well
assessed and used to centre the following functional scan.
The functional scan consisted of a single-slice gradient
Echo-Planar T2* weighted sequence on sagittal plane (TR/TE
707/41ms, average: 12 FOV 215mm2, matrix 192 × 256, a
slice thickness of 10mm, 8 s). This acquisition was repeated
in the same slice for 50 times in the baseline period and
212 times after the ingestion of the oral nutritional intake,
for a total scan duration time of 37min. On the functional
sequence, a circular region of interest (ROI) of 0.5 cm2 was
manually drawn by one of the author (MCC) centred on the
hypothalamus (Figures 1A and 1B).
The hypothalamic area was delineated according to
anatomic landmarks, such as the optic chiasma, the
mammillary bodies, and the floor of the third ventricle, as
previously described.21–23 A second circular ROI of the same
size was delineated in the frontal cortex, anterior of the genu
Figure 1 (A) Midsagittal T1 sequence. Anatomical scan of the hypothalamus-pituitary region. (B) Midsagittal T1 sequence showing region of interest
(ROI) centred on the hypothalamus.
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of the corpus callous, as a control reference area. We
considered this method as the most appropriate to observe
the modifications overtime after oral intake in the whole
hypothalamic area, as demonstrated in similar studies
evaluating the effects of calorie intake on the hypothalamic
activity.12,22,23 At every time point, the mean gray value in
the hypothalamus was calculated, as previously shown.22,23
Functional scans with any BOLD volume displacement
>0.9mm, or a fraction of outliers>0.19 (3dToutcount, AFNI),
were rejected from analysis to prevent the influence of gross
peak and mean head motion.24 This approach allows to
significantly minimize signal loss because of magnetic field
distortions. The imaging processing software (mean curve)
used for analyses was available in the Leonardo® workstation
(Siemens Medical Systems, Erlangen, Germany).
Mean values of signal intensity in the ROI were then
exported on an Excel sheet (Microsoft) and used for statistical
evaluation.
We analysed the BOLD signal intensity at baseline and
before ONS assumption (T0, i.e. time frame 0–50), after
ONS intake (T1, i.e. time frame 51–261), and at the end of
the fMRI scansion (T2, i.e. time 262).
Inflammation and hormonal profile
On the day of anorexia assessment and before fMRI
recording, blood samples were collected from overnight
fasted cancer patients and control subjects. IL-1, IL-6, and
TNF-α levels were measured in duplicate by commercially
available ELISA kits (Abcam, Cambridge, U.K.), as well as
plasma leptin and total ghrelin levels (RayBiotech, Norcross,
GA, U.S.A.)
Statistical analyses
BOLD data were first preprocessed. Images were motion-
corrected, then normalized with affine registration to an
echoplanar imaging template and spatially smoothed. To bet-
ter understand changes in hypothalamic activation, a ROI was
identified and signal modelled only within this region. Our
model included a non-linear time effect to remove signal drift
and high-frequency variation over time. We also included an
additive effect of the stimulus, a group-specific (anorexic,
non-anorexic, and control) intercept, and, when significant,
an interaction between a polynomial function of time,
stimulus and/or the group indicators was included. Standard
errors were obtained through a sandwich estimator to take
into account dependence arising from repeated measure-
ments on the same subjects. We then included subject-
specific serum biomarkers as covariates of the Generalized
Additive Model previously defined.
Significance was evaluated through opportune Wald tests,
and P values were Bonferroni adjusted for multiplicity.
Data are shown as mean ± standard deviation or median
(interquartile range) when variables are not normally
distributed. Percentage (%) of signals change was used to
describe the time course of BOLD intensity and raw data for
the analyses performed at single time point (T0, T1, T2). A P
value ≤0.05 was considered statistically significant.
Results
Participants’ characteristics and prevalence of
anorexia
Thirteen patients and two healthy subjects, serving as
controls, were studied. As previously shown, fMRI allows
for obtaining robust data even if involving a limited number
of subjects.12,19,20 Patients’ anthropometric, clinical, and
nutritional variables are reported in Table 1. Control group in-
cluded one male and one female whose age and BMI (kg/m2)
(65 ± 7.1 years; BMI: 23.95 ± 1.34, respectively) were compa-
rable to anorexic and non-anorexic patients.
In particular, no significant differences were observed
between anorexic and non-anorexic patients regarding
gender distribution, age, anthropometric variables, and
tumour stage.
Based on the results obtained with our criterion standard
for the presence of anorexia (FAACT score ≤ 30), nine patients
(6M, 3 F) were considered as anorexic and four patients
Table 1 Patient’s characteristics according to the presence of anorexia
evaluated using the Functional Assessment of Anorexia/Cachexia Therapy
(FAACT) questionnaire (FAACT score ≤30)
Anorexic (n=9)
Mean± SD
Non-anorexic (n=4)
Mean± SD
Gender
Male 6 1
Female 3 3
Age (years) 71±9.4 76±6.9
Height (m) 1.69±0.08 1.58±0.14
Habitual weight (kg) 73±8.2 61±16.3
% Weight loss in the
previous 6 months
11.7±9.5 9.1±8.8
Body mass index (kg/m2) 22.9± 2.0 24.2±0.3
Visual analog scale 3±2.2 9±1.2*
% eaten 50±27.9 81.3±37.5
Appetite
Increased – –
Usual 3 3
Reduced 6 1
Anorexia questionnaire
Anorexic 8 1
Non-anorexic 1 3
Stage
IIIB 3 4
IV 6 –
*P< 0.0001.
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(1M,3 F) as non-anorexic. Moreover, anorexic patients
showed significantly lower VAS values respect to non-anorexic
(3 ± 2.2 vs. 9 ± 1.2, respectively; P< 0.0001) (Table 1).
Functional magnetic resonance imaging: Blood
Oxygen Level Dependent signals and their
association with oral challenge
Differences between anorexic, non-anorexic, and control at
the time points (inter-groups)
BOLD intensity at T0, T1, and T2 is shown in Table 2. The time
course of BOLD intensity in the 3 groups during the entire
acquisition is shown in Figure 2.
We found significant differences in BOLD signal intensity
between anorexic, non-anorexic patients, and controls, which
were independent from the gender. In particular, anorexic
patients had significant lower BOLD signal intensity, at the
three different time points, respect to non-anorexic patients.
At T0 and T2, anorexic patients had increased hypothalamic
signals vs. controls (P< 0.001), while at T1 anorexic patients
had reduced activity respect to control group (Table 2). Also,
we observed a significantly greater BOLD signal reduction
during T0–T1 period in anorexic patients respect to non-
anorexic (8.5% vs. 6.80%, respectively; P< 0.001).
Conversely, during T1–T2 period we did not find a significant
difference between the increase of the BOLD signal between
anorexic and non-anorexic patients (+0.06% vs. +0.04%,
respectively; P = n.s.). No significant BOLD signal changes
were detected in the control area in all groups at each time
point and overtime.
Differences in anorexic, non-anorexic, and control at the time
points (intra-group)
We observed significant differences in anorexic, non-
anorexic, and control at different time-point. Specifically,
anorexic patients had increased BOLD signal intensity at T0
vs. T1, and at T0 vs. T2 (P< 0.001), while hypothalamic BOLD
signal intensity was significantly reduced at T1 vs. T2
(P< 0.001) (Table 2). Moreover, during T0–T1 period, we
observed a significant reduction (8.51%, CI 8.03–9.19;
P< 0.001) of BOLD signal intensity and a progressive
significant signal increase during T1–T2 period (+0.06%, CI
0.05–0.07; P< 0.001).
Non-anorexic patients had increased BOLD signal intensity
at T0 vs. T1, at T0 vs. T2 (P< 0.001), and T1 vs. T2 (P< 0.001)
(Table 2). Moreover, during T0–T1 period we observed a
significant reduction (6.8%, CI 5.51–7.06; P< 0.001) of
BOLD signal intensity and a subsequent significant signal
increase during T1–T2 period (+0.04%, CI 0.03–0.04;
P< 0.001).
In control group, hypothalamic activity at T0 was
significantly reduced vs. T1 (P = 0.001) and T2 (P = 0.012),
whereas it was reduced at T2 vs. T1 (P = 0.006) (Table 2).
Interestingly, during T0–T1 period, we also observed a
significant reduction of BOLD signal intensity (0.46%, CI
0.29–0.67; P< 0.001), as well as a significant BOLD intensity
increase during T1–T2 period (+0.04%, CI 0.03–0.04;
P< 0.001) (Figure 2).
Inflammation, leptin, and ghrelin
No significant differences in circulating levels of cytokines,
leptin, and ghrelin were observed between the three groups.
However, cytokines, leptin, and ghrelin had a significant im-
pact on BOLD intensity both pre- and post-stimulus (pre-
and post-ONS assumption) (Table 3). In particular, serum
levels of IL-1, IL-6, TNF-α, leptin, and ghrelin were significantly
associated with normalized BOLD signal intensity indepen-
dently from the presence/absence of anorexia and indepen-
dently from the presence NSCLC (Table 3). Moreover, we
Table 2 Blood Oxygen Level Dependent (BOLD) signal intensity (mean
± SD) in the three groups studied at different time points
Time 0 Time 1 Time 2
Anorexic (A) 586± 56 536±62 556±59
Non-anorexic (NA) 668± 33 624±56 615±71
Control (C) 511± 79 542±41 530±58
T0: A vs. NA P< 0.001; A vs. C P< 0.001; NA vs. C P< 0.001.
T1: A vs. NA P< 0.001; A vs. C P< 0.001; NA vs. C P< 0.001.
T2: A vs. NA P< 0.001; A vs. C P< 0.001; NA vs. C P=0.01.
Figure 2 The three different lines indicate the raw BOLD in each group
during functional magnetic resonance imaging scansion at baseline (time
frame 0–50) and after the standard meal assumption (time frame 51–
262). Red line indicates non-anorexic cancer patients, green line indicates
anorexic cancer patients, and blue line indicates control group.
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observed a significant difference regarding the pre- and post-
stimulus effect only for IL-1 and ghrelin levels (P< 0.001).
Discussion
During the last decades, a number of specific physiological
mechanisms have been described in different experimental
settings as determinants of anorexia.25 Nevertheless, the
neurocognitive mechanisms regulating food intake in cancer
patients remain unclear. Recent evidence showed that
anorexic cancer patients display a reduced activation in the
brain regions linked to food stimuli processing.26 In particular,
BOLD activation of brain areas of non-anorexic patients,
including frontal areas in the premotor and prefrontal
cortices, was observed only during stimulation by unpleasant
food. In contrast, anorexic cancer patients showed no brain
activation during stimulation by either pleasant or unpleasant
food images.26
Our study extends these previous observations by
assessing for the first time in anorexic and non-anorexic
cancer patients and control, the effects on hypothalamic
function of a standard meal during a prolonged observational
time. Our dynamic observation included a baseline recording,
to specifically assess possible neurophysiological modifica-
tions after food intake.
The specifically designed protocol of our study allowed
revealing significant different hypothalamic BOLD intensities
in the three groups. Anorexic cancer patients showed a
significant reduction of the hypothalamic signals from
baseline to immediately after meal intake when compared
with non-anorexic patients. Interestingly, anorexic patients
presented increased BOLD activity at baseline and at the
end of the observation period when compared with the con-
trol group, while non-anorexic patients showed the highest
BOLD activity at baseline. Also, anorexic patients had signifi-
cantly reduced BOLD signals at T1 respect to non-anorexic
and control. This evidence appears clinically relevant and
provides neurophysiological background to the impaired
appetite of anorexic cancer patients at baseline and to the
frequently observed worsening of appetite after meal.
The results of our study demonstrate that anorexic, non-
anorexic cancer patients, and healthy controls react
differently to the same food challenge. In anorexic cancer pa-
tients, hypothalamic activity at baseline was significantly
higher than those after food intake and at the end of fMRI
scansion. Also, BOLD activity after the meal was significantly
lower than that at the end of fMRI recording. Hypothalamic
activity of anorexic cancer patients behaved similarly to
non-anorexic patients during the periods T0–T1 and T0–T2.
However, and in contrast with non-anorexic cancer patients,
BOLD signals of anorexic cancer patients in the period
T1–T2 increased significantly, which suggests enhanced
anorexigenic stimuli in response to food intake. During the
period T0–T1, BOLD activity in anorexic and non-anorexic
cancer patients was significantly reduced, but the reduction
observed in anorexic patients was more robust than that
observed in non-anorexic patients. The increase of BOLD
signal during the period T1–T2 was not statistically different
between the anorexic and non-anorexic patients.
Interestingly, although at baseline healthy subjects
presented with the lowest BOLD signal activity respect to
cancer patients (independently from the presence/absence
of anorexia), they responded to food intake similarly to
non-anorexic patients, reducing hypothalamic activity from
the period immediately after meal intake to the end of the
fMRI scansion. Also, hypothalamic signals in control subjects
decreased during the period T0–T1, and increased, as percent
of variation, during the entire period T1–T2. This evidence
might suggest a different response of cancer patients to food
challenge respect to healthy subjects.
We acknowledge that cancer anorexia results from the
complex interaction between activated hypothalamic nuclei
and inhibited areas.7,9 The imaging modality we used does
not allow to capture such a complexity. In this respect, our
data do not allow to identify cancer anorexia as a perturba-
tion of eating behaviour related either to activation or
inhibition of hypothalamic activity. In addition, studies
reported that it is possible to observe different connectivity
Table 3 Association between biomarkers and normalized BOLD signal intensity in anorexic, non anorexic patients, and controls
Biomarker Values° Pre-stimulus effect† Post-stimulus effect†
IL-1* (pg/mL) 8.31 (0.90, 21.2) 0.0003 (0.0001; 0.0004) 0.0155 (0.0111; 0.0219)
IL-6 * (pg/mL) 8.25 (2.06, 11.6) 0.0004 (0.0004; 0.0003) 0.0004 (0.0004; 0.0003)
TNF-α # (pg/mL) 99.2 (3.3, 707.8) 0.000007 (0.000006; 0.000009) 0.000007 (0.000006; 0.000009)
Leptin * (pg/mL) 542.5 (318.9, 620.1) 0.005 (0.003; 0.006) 0.005 (0.003; 0.006)
Ghrelin* (ng/mL) 323.6 (115.0, 2524.9) 0.00001 (0.00000; 0.00002) 0.000025 (0.000022; 0.000029)
Abbreviations: interleukin-1 (IL-1), interleukin-6 (IL-6), tumour necrosis factor (TNF)-α.
°Values: Median (25th, 75th interquartile).
† Blood Oxygen Level Dependent (BOLD) signal intensity (absolute value).
P-value refers to the overall association between the biomarker and normalized BOLD; 95% CI in parentheses.
Differences between pre- and post-stimulus.
*P< 0.001.
#P=0.01.
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profiles in the hypothalamus region when using two seeds in
this area corresponding to a medial and lateral sector of the
hypothalamus.27 This method was able to assess neural re-
sponse to emotional stimuli.27 In our study, we did not aim
to evaluate differences in term of connectivity in different
sectors of the hypothalamus. In this light, we analysed the
whole hypothalamic area which was considered a reliable
method to evaluate differences in BOLD activity before and
after oral calorie intake.12,22,23
Our results strongly point at a functional association
between the presence of anorexia and differences in BOLD
intensity. In particular, cancer patients showed that reduced
appetite is associated with impaired hypothalamic activity.
It is understood that, by using a standard meal, we could
not assess the relative influences of personal food
preferences on BOLD signals.
We acknowledge that food preferences and food aversion
may contribute to the severity of cancer-associated anorexia.
However, they may also confound the interpretation of the
results when the aim of the study is to clarify the relation
between being anorexic and impaired hypothalamic activity
during cancer.
As previously demonstrated, both in humans28 and in
experimental models,29–31 proinflammatory cytokines,
including IL-1, IL-6, and TNF-α are involved in the pathophys-
iology of cancer anorexia. Particularly, IL-1 levels were
significantly increased in the cerebrospinal fluid of anorexic
tumour-bearing rats and inversely correlated with energy
intake.32 Inhibition of TNF-α activity, by the administration
of the recombinant human soluble TNF receptor, resulted in
amelioration of food intake in experimental cancer
anorexia.33 In our study, we could not find significant differ-
ences in the levels of IL-1, IL-6, and TNF-α between anorexic,
non-anorexic patients, and healthy subjects. Conversely, the
circulating levels of cytokines were significantly associated
with normalized BOLD signals before and after oral challenge
in all individuals enrolled for this study, independently from
the presence/absence of anorexia and from the presence of
cancer. The significant association with BOLD signals was also
found for leptin and ghrelin levels. Leptin reduces appetite
and increases energy expenditure via its effects on the cen-
tral nervous system, and in particular via its functional inter-
play with hypothalamic neuropeptides downstream of leptin
signalling regulating food intake and energy homeostasis.34
Similarly, ghrelin levels have been reported to be significantly
increased during secondary anorexia, which in turn may re-
duce food intake by mechanisms of action involving the hy-
pothalamus and the stomach.35
We acknowledge the limitations of our study. We included
a small number of patients, and particularly of healthy
individuals, possibly limiting the interpretation of our results,
although similar experiences using fMRI to investigate the
function of the hypothalamus included comparable number
of participants.12,22,23,26 Moreover, we have not prospectively
assessed the performance of anorexia instruments to
determine whether they are sensitive to changes in appetite
or food intake.
Functional magnetic resonance imaging might not repre-
sent the most accurate methodology to evaluate changes
in hypothalamic activity, particularly after calorie intake,36
when compared with brain perfusion measures, such as
hypothalamic regional cerebral blood flow,37 or other
methods for quantification of the hypothalamic intrinsic
oscillations.38
Finally, we did not find significant differences between
anorexic and non-anorexic cancer patients regarding baseline
values of BMI and body weight change. This might indicate
low accuracy of our instruments in selecting the two groups
of patients. However, we specifically aimed at investigating
the neural implication of the presence/absence of cancer
anorexia, independently from the presence of involuntary
body weight loss.
In conclusion, the results obtained indicate the crucial role
of the central nervous system and, in particular of the
hypothalamus, in the pathogenesis of cancer anorexia.
Data obtained may be extremely useful to provide
neurophysiological basis for the use of novel therapeutic
strategies against cancer anorexia, particularly, for the use
of specific molecules, such as ghrelin and ghrelin mimetics,
able to improve food intake via the direct effects on the
central nervous system.39
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